Pelagos Insurance Capital Limit
NYSE:PLGOInsurance - Diversified
-$0.39 today
- Market cap
- $2.28B
- Beta
- 0.36
- P/E (TTM)
- 5.7
- EPS (TTM)
- $4.04
- Dividend yield
- 2.62%
Volume 0.59M
Average 0.44M
PLGO Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Pelagos Insurance Capital LimitNYSE: PLGO
Net Receivables · Q3 FY2026 · quarter ended Sep 2026
Net receivables falls 15.4% from a year ago
Net receivables stood at $4.4B at the end of Q3 FY2026, down 15.4% from a year earlier and down 3.9% from the prior quarter. Over 3 fiscal years it compounded at +19.7% a year.
Context
- Net receivables amounted to 42.0% of total assets at the end of Q3 FY2026, up 0.3 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -15.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 5.16B USD
- Year-over-year change
- +14.5%
- 4-year CAGR
- +35.0%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.16B | +14.5% |
| FY2024 | 2024-12-31 | 4.51B | +21.8% |
| FY2023 | 2023-12-31 | 3.7B | +23.0% |
| FY2022 | 2022-12-31 | 3.01B | +93.5% |
| FY2021 | 2021-12-31 | 1.56B | — |
Net Receivables vs competitors
How PLGO compares with its peers on the latest reported figures
No competitor Net Receivables figures are available to compare.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 476M | 1.22B | 712.4M | 743M | 873M |
| Short-term Investments | 0 | 2.31B | 605.5M | 570.7M | 576.3M |
| Net Receivables | 1.56B | 3.01B | 3.7B | 4.51B | 5.16B |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 185.9M | 251.7M | 203.6M | 374.6M |
| Total Current Assets | 2.03B | 7.55B | 6.33B | 7.45B | 8.43B |
| Property, Plant & Equipment (Net) | 29.9M | 26.8M | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 515.8M | 786.6M | 877.9M | 1.09B |
| Long-term Investments | 2.78B | 110.8M | 2.74B | 3.26B | 2.66B |
| Tax Assets | 40.3M | 51.2M | 0 | 0 | 0 |
| Other Non-current Assets | 439M | 53M | 173.5M | 176.9M | 272.7M |
| Total Non-current Assets | 3.29B | 757.6M | 3.7B | 4.32B | 4.02B |
| Total Assets | 5.32B | 8.31B | 10.03B | 11.77B | 12.44B |
| Account Payables | 0 | 1.06B | 1.07B | 1.54B | 1.66B |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 1.44B | 2.62B | 3.15B | 3.65B | 4.38B |
| Other Current Liabilities | (1.44B) | 2.05B | 2.45B | 3.13B | 2.61B |
| Total Current Liabilities | 0 | 5.72B | 7B | 8.71B | 9.11B |
| Long-term Debt | 505.3M | 505.9M | 506.6M | 507.3M | 843.2M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.77B | 70.2M | 67.3M | 98M | 91.8M |
| Total Non-current Liabilities | 3.31B | 604.6M | 573.9M | 605.3M | 935M |
| Total Liabilities | 3.31B | 6.33B | 7.58B | 9.32B | 10.04B |
| Common Stock | 2.1M | 1.9M | 1.2M | 1.2M | 1M |
| Retained Earnings | (52.1M) | 500K | 436.6M | 503.6M | 675.9M |
| Accumulated OCI | (11.3M) | (100.8M) | (27M) | 4.5M | 37.1M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 5.2M | 10.3M | 0 | 0 | 0 |
| Total Equity | 2.02B | 1.99B | 2.45B | 2.45B | 2.4B |
| Total Debt | 536.7M | 534.4M | 506.6M | 507.3M | 843.2M |
| Net Debt | 60.7M | (687.6M) | (205.8M) | (235.7M) | (29.8M) |
Pelagos Insurance Capital Limit
NYSE:PLGO
Intrinsic Alpha fair value
Locked
Current Price
$27.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.